Adjuvant and neoadjuvant therapies in high risk localized prostate cancer

被引：0
|
作者：
Giannakopoulos, X.
Stagikas, D.
Charalabopoulos, A.
Sofikitis, N.
Charalabopoulos, K.
机构：
[1] Univ Ioannina, Dept Physiol, Clin Unit, Fac Med, GR-45221 Ioannina, Greece
[2] Univ Ioannina, Dept Urol, GR-45221 Ioannina, Greece
[3] Peterborough Hosp, Dept Surg, Peterborough, Cambs, England
来源：
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2006年 / 25卷 / 04期
关键词：
prostate cancer; adjuvant therapy; neoadjuvant therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this review article adjuvant and neoadjuvant therapies in patients at high risk for localized prostate cancer are presented in some detail. Adjuvant hormone therapy by antiandrogens as well as antineoplastic chemotherapeutic agents such as estramustine and taxanes are referred. Neoadjuvant therapies in addition to systemic therapy before or after local treatment for prostate cancer may improve the outcome of high risk patients otherwise destined to treatment fail. Data regarding some substances used in neoadjuvant therapies such as androgen deprivation therapy and use of rapamycin with its analogs, as well as some novel therapeutic approach strategies are also discussed.
引用
收藏
页码：469 / 473
页数：5
相关论文
共 50 条
  • [21] Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer
    Eapen, Renu S.
    Williams, Scott G.
    Macdonald, Sean
    Keam, Simon P.
    Lawrentschuk, Nathan
    Au, Lewis
    Hofman, Michael S.
    Murphy, Declan G.
    Neeson, Paul J.
    NATURE REVIEWS UROLOGY, 2024, 21 (11) : 676 - 686
  • [22] Neoadjuvant Treatment of High-Risk, Clinically Localized Prostate Cancer Prior to Radical Prostatectomy
    Eugene J. Pietzak
    James A. Eastham
    Current Urology Reports, 2016, 17
  • [23] Prostate cancer specific survival in high risk localized prostate cancer: How high risk is high risk?
    McCann, TR
    Pierorazio, PM
    Olsson, CA
    Benson, MC
    McKiernan, JM
    JOURNAL OF UROLOGY, 2006, 175 (04): : 171 - 172
  • [24] Adjuvant and neoadjuvant therapy in prostate cancer
    Chay, C
    Smith, DC
    SEMINARS IN ONCOLOGY, 2001, 28 (01) : 3 - 12
  • [25] Adjuvant and neoadjuvant treatment of prostate cancer
    Wirth, MP
    Froehner, M
    Hakenberg, OW
    RENAL, BLADDER, PROSTATE AND TESTICULAR CANCER: AN UPDATE, 2001, : 211 - 217
  • [26] Adjuvant and neoadjuvant therapies of pancreatic cancer - A review
    Harris, J
    Bruckner, H
    INTERNATIONAL JOURNAL OF PANCREATOLOGY, 2001, 29 (01) : 1 - 7
  • [27] Taxanes in adjuvant and neoadjuvant therapies for breast cancer
    O'Leary, J
    Volm, M
    Wasserheit, C
    Muggia, F
    ONCOLOGY-NEW YORK, 1998, 12 (01): : 23 - 27
  • [28] The Promise of Neoadjuvant and Adjuvant Therapies for Renal Cancer
    Leow, Jeffrey J.
    Ray, Shagnik
    Dason, Shawn
    Singer, Eric A.
    Chang, Steven L.
    UROLOGIC CLINICS OF NORTH AMERICA, 2023, 50 (02) : 285 - 303
  • [29] THE ROLE OF ADJUVANT TREATMENT STRATEGIES AFTER SURGERY FOR HIGH-RISK LOCALIZED PROSTATE CANCER
    Spahn, M.
    Joniau, S.
    Gontero, P.
    Tombal, B.
    Walz, J.
    Hsu, C. Y.
    Marchioro, G.
    Van Der Eeckt, K.
    Bader, P.
    Bangma, C.
    Frohneberg, D.
    Graefen, M.
    Huland, H.
    Schroder, F.
    Tizzani, A.
    Van Cangh, P.
    Van Poppel, H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 251 - 251
  • [30] TREATMENT OF LOCALIZED HIGH RISK PROSTATE CANCER
    Tombal, B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 22 - 23
12345